Abstract Details

Title The Prevalence of Sjogren’s Syndrome-associated Antibodies and Sjogren’s Syndrome in patients with anti-Myelin Oligodendrocyte Glycoprotein Antibodies

Topic Autoimmune Neurology

Presentation(s) P8 - Poster Session 8 (8:00 AM-9:00 AM)

Poster/Presentation
Number 8-018

Objective To describe the prevalence of Sjogren’s Syndrome (SS)-associated antibodies and clinical SS in patients with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies.

Background While there is a known association between SS and neuromyelitis optica spectrum disorder (NMOSD), little is known about the prevalence of SS-associated antibodies and clinical SS in patients with anti-MOG antibodies.

Design/Methods We conducted a chart review to evaluate for the presence of SS-associated antibodies (anti-SSA/Ro and anti-SSB/La) and clinical SS in patients with positive MOG antibodies who were evaluated by providers at our institution between January 2000 and August 2024.

Results Among 282 patients with anti-MOG antibodies, results of anti-SSA/Ro and anti-SSB/La antibody testing were available in 133 (47.2%). In this group, median age was 41.5 years (range 8-82 years); and 87 (65.4%) identified as female, 43 (32.3%) as male and 3 (2.2%) as non-binary. Information about race was available in 131 (98.5%) patients, of whom 102 (77.9%) identified as white or Caucasian, 12 (9.1%) as black or African American, 10 (7.6%) as Asian and 7 (5.3%) as other; and 8 (6.2%) of 129 patients identified as Hispanic or Latino. Anti-SSA/Ro was positive in 4 patients (3.0%) and equivocal in 1 patient (0.75%). Anti-SSB/La antibodies were positive in 1 patient (N = 1, 0.75%). Two (1.5%) patients with SS-associated antibodies were considered to have clinical SS. There were an additional 6 patients in whom clinical SS was suspected, but was not confirmed (negative antibodies without other confirmation testing, or lack of antibody testing).

Conclusions We estimate the prevalence of anti-SSA/Ro antibody positivity, anti-SSB/La antibody positivity, and clinical SS in patients with anti-MOG antibodies to be 3.0%, 0.75% and 1.5% respectively. Rates of anti-SSA positivity appear to be higher in patients with anti-MOG antibodies compared to the general population in the United States (0.54%), but lower than in NMOSD (26.3%).

Authors/Disclosures
Mattia Wruble, MD PRESENTER	The institution of Dr. Wruble has received research support from Alexion. The institution of Dr. Wruble has received research support from Roche.
Philippe-Antoine Bilodeau, MD (Massachusetts General Hospital)	Dr. Bilodeau has nothing to disclose.
Anastasia Vishnevetsky, MD (Massachusetts General Hospital)	The institution of Dr. Vishnevetsky has received research support from National MS Society. The institution of Dr. Vishnevetsky has received research support from NIH (NeuroNext).
Monique Anderson, MD, PhD (Mass General Hospital)	Dr. Anderson has nothing to disclose.
Takahisa Mikami, MD (Massachusetts General Hospital)	Dr. Mikami has nothing to disclose.
Rebecca Salky	Rebecca Salky has nothing to disclose.
Gabriela Romanow (Massachusetts General Hospital)	Gabriela Romanow has nothing to disclose.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital)	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School)	Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
Shamik Bhattacharyya, MD, FAAN (Brigham and Women's Hospital)	Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroLambda. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Continuum. Dr. Bhattacharyya has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Dr. Bhattacharyya has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Merck. The institution of Dr. Bhattacharyya has received research support from Alexion Pharmaceuticals. The institution of Dr. Bhattacharyya has received research support from National Institute of Health. The institution of Dr. Bhattacharyya has received research support from UCB. The institution of Dr. Bhattacharyya has received research support from Genentech. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��